Montag A & Associates Inc. Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Montag A & Associates Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 97,990 shares of the company’s stock after selling 9,563 shares during the period. Montag A & Associates Inc.’s holdings in Johnson & Johnson were worth $14,171,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Tanglewood Legacy Advisors LLC increased its stake in Johnson & Johnson by 11.6% during the 4th quarter. Tanglewood Legacy Advisors LLC now owns 6,131 shares of the company’s stock worth $887,000 after buying an additional 637 shares during the period. Roxbury Financial LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $732,000. Guyasuta Investment Advisors Inc. lifted its stake in shares of Johnson & Johnson by 0.9% in the fourth quarter. Guyasuta Investment Advisors Inc. now owns 268,896 shares of the company’s stock worth $38,888,000 after acquiring an additional 2,289 shares in the last quarter. Aveo Capital Partners LLC boosted its holdings in Johnson & Johnson by 17.0% in the fourth quarter. Aveo Capital Partners LLC now owns 8,207 shares of the company’s stock valued at $1,187,000 after purchasing an additional 1,194 shares during the last quarter. Finally, CapWealth Advisors LLC grew its stake in Johnson & Johnson by 1.5% during the 4th quarter. CapWealth Advisors LLC now owns 137,249 shares of the company’s stock valued at $19,849,000 after purchasing an additional 1,963 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Barclays upped their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Wells Fargo & Company lowered their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Leerink Partners dropped their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Guggenheim lifted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $155.04 on Wednesday. The firm has a market capitalization of $373.27 billion, a price-to-earnings ratio of 23.31, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The stock’s fifty day moving average is $148.00 and its 200-day moving average is $155.91. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.